New insider activity at BridgeBio Pharma ( (BBIO) ) has taken place on May 7, 2025.
In recent transactions involving BridgeBio Pharma stock, CAO Maricel Apuli sold 1,026 shares, amounting to $39,501. Additionally, Director Andrew Lo executed a significant sale of 100,000 shares, totaling $3,849,000.
Recent Updates on BBIO stock
BridgeBio Pharma has experienced significant developments recently, highlighted by the successful launch of its drug Attruby, which generated $36.7 million in revenue in its first quarter. This success, alongside strong pipeline progress and better-than-expected financial performance, has led to multiple analysts raising their price targets for the company. Scotiabank, UBS, and BofA have all increased their price targets, citing impressive commercial execution and the strong start of Attruby’s launch as key factors. Despite increased SG&A expenses due to the commercial rollout, the company’s overall financial health remains robust, with a strategic market positioning that enhances its competitive edge. The positive outlook is further supported by upcoming Phase 3 readouts and a continued focus on innovative, cost-effective therapies.
Spark’s Take on BBIO Stock
According to Spark, TipRanks’ AI Analyst, BBIO is a Neutral.
BridgeBio Pharma’s overall score reflects a strong market momentum and positive earnings call and corporate developments, offset by financial instability and valuation concerns due to unprofitability and high leverage.
To see Spark’s full report on BBIO stock, click here.
More about BridgeBio Pharma
YTD Price Performance: 35.53%
Average Trading Volume: 3,125,332
Technical Sentiment Signal: Buy
Current Market Cap: $7.32B